TEVA Pharmaceutical is a global pharmaceutical company that develops, produces and markets generic drugs. Its subsidiary, formally known as Sicor, is based in Irvine California and is responsible for the production of injectable suspensions and injectable complex drug delivery systems. TEVA USA’s Irvine office markets products from diverse therapeutic areas including analgesic, anti-infective, cardiovascular, oncology, CNS, dermatological and anti-inflammatory.
TEVA’s global structure is vertically-integrated with three main business segments, finishing dosage generic pharmaceuticals, active pharmaceutical ingredients and proprietary branded pharmaceuticals. TEVA’s corporate structure is one of its core competencies.
TEVA has a presence in over sixty countries around the world and employees approximately 26,000 people. TEVA’s revenue ranks among the top 20 among all pharmaceutical companies and is the largest generic drug manufacturer in the world. TEVA markets its products to chains, wholesalers, distributors, hospitals and government agencies. 80% of TEVA’s sales (8.4 Billion in 2006) are generated from Europe and North America. TEVA has been consistently recognized as having one of the best ANDA approval records in the industry.
The corporate headquarters are presently located in Israel, where TEVA was founded in 1901 as Salomon, Levin and Elstein LTD. These men distributed imported medicines on the backs of camels and donkeys. Several pharmaceutical companies were established in the Middle East during the 1930’s as immigrants arrived from Europe. TEVA raised money through the Tel-Aviv Stock Exchange in 1951 and in 1964 merged with Assia and Zori. In 1980, TEVA was focused on becoming ...